PT
About
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 10,621 investors are based in New York, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- New York, US
Contact Information
linkedin.com/in/••••••••
Find more investors like Prevail
Search Investors